SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6448-6458

  Blanc, Veronique ^a   Bousseau, Anne ^a   Caron, Anne ^a   Carrez, Chantal ^a   Lutz, Robert J ^b   Lambert, John M ^b  

^a SANOFI   (France)

^b IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFM 11; AFM 12; ALEMTUZUMAB; ANTIBODY CONJUGATE; BLINATUMOMAB; CD19 ANTIGEN; COMBOTOX; DACETUZUMAB; DM 4; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; MAYTANSINE; MAYTANSINE DERIVATIVE; MDX 1206; MDX 1342; MEDI 551; MONOCLONAL ANTIBODY; MOR 208; OFATUMUMAB; PACLITAXEL; RITUXIMAB; SAR 3419; SGN 19A; TOSITUMOMAB I 131; TRU 016; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LYMPHOMA; BLOOD TOXICITY; CELL CYCLE ARREST; CELL DEATH; CORNEA DISEASE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TARGETING; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MAYTANSINE; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054095609     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0485     Document Type: Review

References (60)

1. American Cancer Society [homepage on the Internet]. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society 2010 [cited 2011 Sept 13]. Available from: http://www.cancer.org/acs/groups/ content/@nho/documents/ document/acspc-024113.pdf.
2. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803-11.
3. Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leuk Lymphoma 2010;51[Suppl 1]:20-7.
4. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168: 469-76. (Pubitemid 351559319)
5. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, WilliamsME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. (Pubitemid 28363048)
6. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8: 288-334.
7. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
8. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 2008;22:941-52, ix.
9. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85-96.
10. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non- Hodgkin's lymphoma. J Clin Oncol 2011;29:1876-84.
11. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97.
12. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011;17:6406-16.
13. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405.
14. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47.
15. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
16. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27.
17. Fraser G, Smith CA, Imrie K, Meyer R, et al. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007;14:96-109. (Pubitemid 47204237)
18. Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011;5: 45-53.
19. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345-52.
20. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94.
21. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13. (Pubitemid 46842705)
22. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:228-35.
23. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011;317: 1255-60.
24. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden- Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007;110:2569-77. (Pubitemid 47527052)
25. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93.
26. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85.
27. Younes A, Gordon L, Kim S, Romaguera J, Copeland AR, de Castro Farial S, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory Bcell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2009;114:585.
28. Lambert JM. Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer. Drugs Future 2010;35:471-80.
29. Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. Immunol Res 2005;31:119-31. (Pubitemid 40631383)
30. de Rie MA, Schumacher TN, van Schijndel GM, van Lier RA, Miedema F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 1989;118:368-81. (Pubitemid 19051457)
31. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983;131:244-50. (Pubitemid 13067888)
32. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385-97.
33. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33. (Pubitemid 14120390)
34. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008;68:6300-5.
35. Lutz RJ, Zuany-Amorim C, Vrignaud P, Mayo MF, Guerif S, Xie H, et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res 2006;47:3731.
36. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximabsensitive and -resistant lymphomas. Blood 2009;113:4352-61.
37. Ingle GS, Chan P, Elliott JM, Chang WS,Koeppen H, Stephan J-P, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol 2008;140:46-58. (Pubitemid 350233252)
38. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302-13. (Pubitemid 30226212)
39. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, et al. A phase 1 study of Combotox in pediatric patients with refractory Blineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41.
40. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408. (Pubitemid 44036683)
41. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 1994;91: 969-73. (Pubitemid 24048490)
42. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14.
43. Al-Katib AM, Aboukameel A, Mohammad R, Bissery M-C, Zuany- Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:4038-45.
44. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoidconjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010;9:2689-99.
45. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
46. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27.
47. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
48. Erickson HK, Provenzano CA, Mayo MF, Widdison WC, Audette C, Leece B, et al. Target-cell processing of the anti-CD19 antibody maytansinoid conjugate SAR3419 in preclinical models [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5473.
49. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. Tumor delivery and in vivo processing of disulfide- linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92.
50. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207. (Pubitemid 9109517)
51. Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol 2011;727:1-19.
52. Coiffier B, Ribrag V, Dupuis J, Tilly H, Haioun C, Morschhauseret F, et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 2011;29 (suppl):8017.
53. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44. (Pubitemid 34517637)
54. Qin A, Watermill J, Mastico RA, Lutz RJ, O'Keeffe J, Zildjian S, et al. The pharmacokinetics and pharmacodynamics of IMGN242 (huC242- DM4) in patients with CanAg-expressing solid tumors. J Clin Oncol 2008;26(15S):3066.
55. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803. (Pubitemid 46657376)
56. Burris HA3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
57. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN35) for relapsed CD30-positive lymphomas. N Engl J Med 2011;363:1812-21.
58. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 2010;5:140-7.
59. Janeway C, Travers P, Walport M, Shlomchik MJ. Immunobiology: the immune system in health and disease. 6th ed. New York: Garland Publishing; 2004.
60. Uckun FM. Regulation of human B-cell ontogeny. Blood 1990;76: 1908-23.